Table 1. Characteristics of studies included in this meta-analysis.
| Author | Number of patients | Year (country) | HIF-1α positive(negative) | Pathological type | Histological type | FIGO stage | Histological grade | Lymph node metastasis | 5-years overall survival rate | 5-years disease free survival rate |
|---|---|---|---|---|---|---|---|---|---|---|
| Ovarian cancer | (cancer/borderline/ benign) | (serous/clear cell/others) | (I–II/III–IV) | (G1/G2/G3) | (yes/no) | (<5/≥5) | (<5/≥5) | |||
| Daponte14 | 120 | 2008(Greece) | 61(59) | 78/22/20 | - | - | - | - | - | - |
| Shimogai13 | 66 | 2008 (Japan) | 11(55) | 66/-/- | 48/5/13 | 22/44 | - | 25/41 | 24/42 | 11/55 |
| Yu15 | 117 | 2012 (China) | 59(58) | 87/-/30 | 75/12* | 45/44 | - | 42/45 | 53/34 | - |
| Birner10 | 172 | 2001(Austria) | 116(56) | 102/50/20 | 64/8/30 | - | - | - | - | - |
| Osada16 | 107 | 2007 (Japan) | 82(25) | 72/17/18 | - | 48/24 | 32/30/10 | - | - | - |
| Shen17 | 63 | 2013 (China) | 55(8) | 63/-/- | - | 44/19 | 19/17/16 | - | - | - |
| Su18 | 81 | 2011 (China) | 40(41) | 35/22/24 | - | 13/22 | 4/17/14 | - | - | - |
| Yu19 | 30 | 2009 (China) | 26(4) | 30/-/- | 18/2/10 | 12/18 | 10/10/8 | - | - | - |
| Liu20 | 171 | 2012 (China) | 80(91) | 96/-/45 | 45/8/43 | 30/66 | 24/40/32 | - | - | - |
| Chen21 | 62 | 2011 (China) | 29(33) | 62/-/- | 40/22* | 26/36 | 25/37 △ | 36/26 | 44/18 | - |
| Fu22 | 119 | 2008 (China) | 70(49) | 101/-/- | 51/9/41 | 53/48 | - | - | - | - |
| Guo23 | 108 | 2010 (China) | 39(66) | 58/-/30 | - | 20/38 | 18/28/12 | 27/31 | - | - |
| Naka26 | 52 | 2007 (Japan) | 36(16) | 52/-/- | 29/9/14 | -/52 | 19/14/10 | - | - | - |
| Ji25 | 116 | 2013 (China) | 70(46) | 41/20/27 | - | 20/21 | - | 27/14 | - | - |
| Nakayama26 | 60 | 2002 (Japan) | 30(30) | 60/-/- | 29/17/14 # | 23/37 | 17/16/22 | - | - | - |
| Iida27 | 102 | 2008 (Japan) | 91(11) | 39/32/31 | - | - | - | - | - | - |
| Chen28 | 164 | 2012 (China) | 62(102) | 124/-/- | 80/44 ▲ | 53/71 | 49/75 △ | 50/74 | - | - |
| Li29 | 141 | 2011(China) | 66(75) | 60/21/30 | 40/20* | 19/41 | 23/37 | 36/24 | - | - |
| Wong30 | 53 | 2003(USA) | 22(31) | 37/-/16 | 29/2/6 | -/37 | - | - | - | - |
| Luo31 | 308 | 2005(China) | 208(100) | 238/19/38 | 148/20/70 | 77/161 | 53/101/84 | - | - | - |
| Wang32 | 145 | 2008(China) | 86(79) | 112/9/18 | 58/33/31 # | 46/76 | 24/48/38 | - | - | - |
| Tong34 | 31 | 2008(China) | 26(5) | 31/-/- | 31/-/- | - | - | 21/10 | - | 21/10 |
| Li33 | 73 | 2009(China) | 35(38) | 37/19/- | - | 13/24 | 12/25 $ | 27/10 | - | - |
| Miyazawa35 | 36 | 2009(Japan) | 21(2) | 23/2/11 | 5/7/11 | - | - | - | - | - |
| Yasuda36 | 74 | 2008(Japan) | 69(5) | 74/-/- | 21/18/35 | - | - | - | - | - |
| Cervical cancer | (cancer/CIN/normal) | (squamous/ others) | (I–II/III–IV) | (G1/G2/G3) | (yes/no) | (<5/≥5) | (<5/≥5) | |||
| Cheng37 | 158 | 2013(China) | 63(35) | 98/32/28 | 98/- | 57/41 @ | 42/35/21 | 39/59 | - | - |
| Kim38 | 745 | 2013(Korea) | 60(91) | 179/209/357 | 144/35 | 174/5 | - | - | 17/134 | 31/120 |
| Huang39 | 74 | 2014(China) | 39(35) | 74/-/- | 58/16 | 35/39 $ | 38/36 △ | 17/57 | - | - |
| Dellas40 | 44 | 2008(Germany) | 32(12) | 44/-/- | - | 9/35 | - | - | 19/25 | - |
| Birner8 | 106 | 2000(Austria) | 20(71) | 91/10/5 | - | 91/- | - | - | 17/74 | 28/63 |
| Bachtiary12 | 67 | 2003(Austria) | 32(35) | 67/-/- | 59/8 | 40/27 | 7/34/17 | 21/46 | - | - |
| Li41 | 120 | 2010(China) | 90(30) | 40/40/40 | 40/- | 40/- | 10/21/9 | 10/30 | - | - |
| Guo42 | 189 | 2008(China) | 93(96) | 79/90/20 | 79/- | 54/25 | 17/36/26 | - | - | - |
| Liu43 | 93 | 2008(China) | 26(19) | 45/28/20 | 45/- | 45/- | 29/16 △ | - | - | - |
| Zhang44 | 54 | 2009(China) | 28(26) | 34/10/10 | 23/11 | 34/- | 13/21 $ | 19/15 | - | - |
| Acs45 | 170 | 2003(USA) | 143(27) | 15/70/85 | 15/- | 15/- | - | - | - | - |
| Hutchison46 | 99 | 2004(United Kingdom) | 68(31) | 99/-/- | - | 57/42 | 17/57/14 | - | - | - |
| No47 | 116 | 2009(Korea) | 40(76) | 36/39/41 | - | - | 11/25 | - | - | |
| Ishikawa48 | 38 | 2004(Japan) | 20(18) | 38/-/- | 38/- | -/38 | - | - | - | 17/21 |
| Haugland49 | 101 | 2002(Canada) | 23(22) | 45/-/- | 33/12 | 30/15 | - | 11/34 | - | - |
| Burri50 | 91 | 2003(Switzerland) | 46(32) | 78/-/- | 63/15 | 9/43/26& | - | 30/47 | - | - |
| Markowska51 | 106 | 2007(Poland) | 81(25) | 106/-/- | 106/- | - | 29/46/31 | - | - | - |
| Endometrial cancer | (cancer/borderline/ normal) | (type 1/ type 2) | (I–II/III–IV) | (G1/G2/G3) | (yes/no) | (<5/≥5) | (<5/≥5) | |||
| Ozbudak52 | 100 | 2008(Turkey) | 45(55) | 100/-/- | 100/- | 69/31 | 60/25/15 | - | - | - |
| Feng53 | 187 | 2013(China) | 100(87) | 124/28/35 | 124/- | 101/23 | 57/41/26 | 31/93 | - | - |
| Espinosa54 | 64 | 2010(Italy) | 17(32) | 64/-/- | 64/- | 24/25 | 14/22/28 | - | - | - |
| Seeber69 | 108 | 2010(Netherlands) | 54(39) | 93/-/- | 75/18 | 75/18 | 28/47/18 | - | - | 18/72 |
| Pijnenborg55 | 65 | 2007(Netherlands) | 14(51) | 65/-/- | 65/- | 60/5 | 20/29/16 | - | - | 40/25 |
| Acs9 | 166 | 2004(USA) | 79(28) | 107/-/59 | 74/33 | 65/42 | 36/20/51 | - | - | - |
| Pansare56 | 149 | 2007(USA) | 54(90) | 149/-/- | 80/41 | 114/30 | 42/66 $ | - | - | - |
| Horrée57 | 79 | 2007(Netherlands) | 48(31) | 39/23/17 | 39/- | 23/16 | 6/21/12 | - | - | - |
| Koda58 | 85 | 2007(Poland) | 55(30) | 60/-/25 | - | 29/31 | 8/44/8 | - | - | - |
| Aybatli59 | 94 | 2011(Turkey) | 28(66) | 94/-/- | 76/18 | 64/30 | 36/30/28 | 34/60 | - | 9/85 |
| Yeramian60 | 93 | 2011(Spain and USA) | 26(55) | 93/-/- | 93/- | - | 26/35/21 | - | - | 9/72 |
| Li61 | 54 | 2008(China) | 20(34) | 42/-/12 | 36/6 | 21/21 | 8/34 $ | 32/10 | - | - |
| Zhai62 | 62 | 2007(China) | 25(37) | 42/-/20 | 42/- | 28/14 | 25/17 △ | 16/26 | - | - |
| Pan63 | 93 | 2011(China) | 51(42) | 52/23/18 | 52/- | 32/20 | 17/17/18 | 11/41 | - | - |
| Song64 | 40 | 2009(China) | 26(14) | 30/10/- | 20/10 | 27/3 | - | - | - | - |
| Sivridis2 | 106 | 2002(Greece) | 40(41) | 81/-/25 | 81/- | 81/- | 50/31 $ | - | 10/71 | - |
| Wang65 | 125 | 2010(China) | 65(33) | 105/-/20 | 105/- | 92/13 | 53/40/12 | - | 12/86 | - |
*: serous/mucinous;
#: serous/mucinous/others;
▲: serous/others;
△: G1-G2/G3;
$: G1/G2-G3;
@: Ia1-IIa/IIb-IIIb; $: Ia2-Ib1/Ib2-IIb; &: Ib-IIa/IIb-IIIa/IIIb-IVa